I make a donation

DOSAPI

Evaluate the impact of the interaction between the proton pump inhibitors and platelet inhibitors clopidogrel and prasugrel in coronary stable patients

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

Bourses ACTION & PHRA 2022

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Prix de Recherche Pr Jean-Philippe COLLET

objectif

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition

date de réalisation

2010

nombre de patients

nombre de centres participants

Monocentric (Pitié-Salpêtrière)

type de financement

Private (Medco Health Solutions, Inc.)

Référence

NCT01175200

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction (DOSAPI)

Study Description

This study will establish the optimal therapeutic strategy for patients with a coronary artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for treatment/prevention of GI ulceration.

source clinicaltrials.gov

Publication

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study
Jean-Philippe Collet, Jean-Sébastien Hulot, Jérémie Abtan, Ghalia Anzaha, Mathieu Kerneis, Johanne Silvain, Guillaume Cayla, Stephen A O'Connor, Olivier Barthélémy, Farzin Beygui, Sophie Galier, Delphine Brugier, Eric J Stanek, Scott L Charland, Vanessa Gallois, Gilles Montalescot, DOSAPI investigators
Publicated in European Journal of Clinical Pharmacology

Autres études

ANCHOR

En cours

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients

AFLOAT

En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.

AFIJI

En cours

Impact of genetics on occuring of coronary diseases in young patients and the pharmacogenetic of clopidogrel and its impact on the prognosis of patients having had angioplasty